Aim of this study was to determine the endogenous levels of ALC and other acyl-L-carnitines in different groups of subjects along the continuum from normal to SMC, MCI, up to AD, and verify if such metabolites could be used as potential serum biomarkers of AD progression. The gene discussed is ALLC; the disease is Alzheimer disease.